Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma | Zendy

Georgina V. Long | Zendy; Axel Hauschild | Zendy; Mario Santinami | Zendy; Victoria Atkinson | Zendy; Mario Mandalà | Zendy; Vanna ChiarionSileni | Zendy; James Larkin | Zendy; Marta Nyakas | Zendy; Caroline Dutriaux | Zendy; Andrew Haydon | Zendy; Caroline Robert | Zendy; Laurent Mortier | Zendy; Jacob Schachter | Zendy; Dirk Schadendorf | Zendy; Thierry Lesimple | Zendy; Ruth Plummer | Zendy; Ran Ji | Zendy; Pingkuan Zhang | Zendy; Bijoyesh Mookerjee | Zendy; Jeff Legos | Zendy; Richard Kefford | Zendy; Reinhard Drummer | Zendy; John M. Kirkwood | Zendy

Open Access

Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma

Author(s) -

Georgina V. Long,

Axel Hauschild,

Mario Santinami,

Victoria Atkinson,

Mario Mandalà,

Vanna ChiarionSileni,

James Larkin,

Marta Nyakas,

Caroline Dutriaux,

Andrew Haydon,

Caroline Robert,

Laurent Mortier,

Jacob Schachter,

Dirk Schadendorf,

Thierry Lesimple,

Ruth Plummer,

Ran Ji,

Pingkuan Zhang,

Bijoyesh Mookerjee,

Jeff Legos,

Richard Kefford,

Reinhard Drummer,

John M. Kirkwood

Publication year - 2018

Publication title -

skin the journal of cutaneous medicine

Language(s) - English

Resource type - Journals

ISSN - 2574-1624

DOI - 10.25251/skin.2.supp.43

Subject(s) - dabrafenib , trametinib , placebo , medicine , adjuvant , stage (stratigraphy) , melanoma , oncology , dermatology , cancer research , pathology , vemurafenib , mapk/erk pathway , chemistry , metastatic melanoma , biology , phosphorylation , paleontology , biochemistry , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research